Royal jelly prevents osteoporosis in rats: Beneficial effects in ovariectomy model and in bone tissue culture model

Evidence-based Complementary and Alternative Medicine

Volumn 3, Issue 3, 2006, Pages 339-348

  Hidaka, Saburo ^a   Okamoto, Yoshizo ^b   Uchiyama, Satoshi ^c   Nakatsuma, Akira ^d   Hashimoto, Ken ^d   Ohnishi, S Tsuyoshi ^e   Yamaguchi, Masayoshi ^c  

^a Fukuoka College of Health Sciences   (Japan)

^b FUKUOKA DENTAL COLLEGE   (Japan)

^c UNIVERSITY OF SHIZUOKA   (Japan)

^d Yamada Apiculture Center Inc   (Japan)

^e Philadelphia Biomedical Research Institute   (United States)

Author keywords

Bone mineral density; Bone tissue culture; Ovariectomized rats; Post menopausal osteoporosis model; Protease treated RJ; Royal jelly

Indexed keywords

ESTRADIOL; PROTEINASE; ROYAL JELLY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE DENSITY; BONE MINERAL; BONE TISSUE; CALCIUM BONE LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FOOD INTAKE; MALE; NONHUMAN; OSTEOCLAST; OSTEOPOROSIS; OVARIECTOMY; PRIORITY JOURNAL; RAT; TISSUE CULTURE; UTERUS WEIGHT;

EID: 33748136432     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1093/ecam/nel019     Document Type: Article

References (42)

1. Fugh-Berman A. Alternative Medicine: What Works. USA: Lippincott & Williams & Wilkinson Inc., 1997.
2. Costa Rosa LFBP. Exercise as a time-conditioning effector in chronic disease: a complementary treatment strategy. Evid Based Complement Alternat Med 2004;1:63-70.
3. Tsao JCI, Zeltzer LK. Complementary and alternative medicine approaches for pediatric pain: a review of the state-of-the-science. Evid Based Complement Alternat Med 2005;2:149-59.
4. Riggs BL, Melton LJ III. Osteoporosis: Etiology, Diagnosis, and Management. 2nd edn, Philadelphia, USA: Lipincott-Raven, 1995.
5. Schmidt IU, Walkley GK, Turner RT. Effects of estrogen and progesterone on tibia histomorphometry in growing rats. Calcif Tissue Int 2000;67:47-52.
6. Kalu DN. The ovariectomized rat model for postmenopausal bone loss. Bone Miner 1991;15:175-92.
7. Nishida A, Ito M, Uetani M, Nakayama T, Tanaka T. Effect of etidronate on three-dimensional trabecular structure in ovariectomized or sciatic neuretomized rats. J Bone Miner Metab 2004;22:335-40.
8. Mochizuki K, Inoue T. Effect of salmon calcitonin on experimental osteoporosis induced by ovariectomy and low-calcium diet in the rat. J Bone Miner Metab 2000;18:194-207.
9. Morris HA, Need AG, Horowitz M, O'Leughlin PD, Nordin BEC. Calcium adsorption in normal and osteoporotic postmenopausal women. Calcif Tissue Int 1991;48:240-43.
10. Uchiyama Y, Higuchi Y, Takeda S, Masaki T, Shira-Ishi A, Sato K, et al. ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Bone 2002;30:582-8.
11. Terasawa K. Kampo: Japansese-Oritental Medicine - Insights from Clinical Cases (co-translated by Bacowsky H, Gerz A). Tokyo, Japan: Standard McIntyre K.K., 1993.
12. Hidaka S, Okamoto Y, Nakajima K, Suekawa M, Liu SY. Preventive effects of traditional Chinese (Kampo) medicines on experimental osteoporosis induced by ovariectomy in rats. Calcif Tissue Int 1997;61:239-46.
13. Hidaka S, Okamoto Y, Yamada Y, Kon Y, Kimura T. A Japanese herbal medicine, Chujo-to has a beneficial effect on the osteoporosis in rats. Phytother Res 1999;13:14-9.
14. Hidaka S, Okamoto Y, Miyazaki K, Uesugi T. Evaluation of a soybean product Fujiflavone P40 as an antiosteoporotic agent in rats. Phytother Res 2003;17:112-9.
15. Hidaka S, Okamoto Y, Yamada Y, Miyazaki K, Kimura T. Alterations in the periodontium after ovariectomy in rats: the effects of a Japanese herbal medicine, Chujo-to. Phytother Res 2000;14:527-33.
16. Inoue S, Koya-Miyata S, Ushio S, Iwaki K, Ikeda M, Kurimoto M. Royal jelly prolongs the life span of C3H/HeJ mice: correlation with reduced DNA damage. Exp Gerontol 2003;38:965-9.
17. Kamakura M, Mitani N, Fukuda T, Fukushima M. Antifatigue effect of fresh royal jelly in mice. J Nutr Sci Vitaminol 2001;47:394-401.
18. Okamoto I, Taniguchi Y, Kunikita T, Kohno K, Iwaki K, Ikeda M, et al. Major royal jelly protein 3 modulates immune responses in vitro and in vivo. Life Sci 2003;1:2029-45.
19. Bincoletto C, Eberlin S, Figueiredo CA, Luengo MB, Queiroz ML. Effects produced by royal jelly on haematopoiesis: relation with host resistance against Ehrlich ascites tumour challenge. Int Immunopharmacol 2005;5:679-88.
20. Vittek J. Effect of royal jelly on serum lipids in experimental animals and humans with atherosclerosis. Experientia 1995;51:927-35.
21. Matsui T, Yukiyoshi A, Doi S, Sugimoto H, Yamada H, Matsumoto K. Gastrointestinal enzyme production of bioactive peptides from royal jelly protein and their antihypertensive ability in SHR. J Nutr Biochem 2002;13:80-6.
22. Fujii A, Kobayashi S, Kuboyama N, Furukawa Y, Kaneko Y, Ishihama S, et al. Augmentation of wound healing by royal jelly (RJ) in streptozotocin-diabetic rats. Jpn J Pharmacol 1990;53:331-7.
23. Takenaka T. Chemical composition of royal jelly. Honeybee Sci 1982;3:69-74.
24. Fujiwara S, Imai J, Fujiwara M, Yaeshima T, Kawashima T, Kobayashi K. Apotent antibacterial protein in royal jelly. J Biol Chem 1990;265:11333-7.
25. Vittek J, Slomiany BL. Testosterone in royal jelly. Experientia 1984;40:104-6.
26. Kuratsu N, Isohama Y, Yamashita Y, Takei H, Tokuomi K, Inoue M, et al. A study on estrogen-like activity of royal jelly. Proc Med Pharm Soci WAKAN-YAKU, 2003;20 (Suppl):161 (in Japanese).
27. Nakasa T, Okinaka O, Nakatsuka M. Promotion effect of calcium absorption by protease-treated royal jelly. Food Dev 1999;34:42-4 (in Japanese).
28. Yamaguchi M, Oishi H, Suketa Y. Stimulatory effect of zinc on bone formation in tissue culture. Biochem Pharmacol 1987;36:4007-12.
29. Willis JB. Determination of calcium in blood serum by atomic absorption spectroscopy. Nature (London) 1960;186:249-50.
30. Takahashi N, Yamana H, Yoshiki S, Roodman GD, Mundy GR, Jones SJ, et al. Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology 1988;122:1373-82.
31. Mundy GR, Roodman GD. Osteoclast ontogeny and function. In: Peck WA (ed). Bone and Mineral Research. Amsterdam: Elsevier Science, 1987, 209-79.
32. Burstone MS. Histochemical demonstration of acid phosphatases with naphthol AS-phosphates. J Natl Cancer Inst 1958;21:523-39.
33. Minkin C. Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int 1982;34:285-90.
34. Tarttelin MF, Gorski RA. The effect of ovarian steroids on food and water intake and body weight in the female rats. Acta Endocrinol 1978;72:551-68.
35. Nishikawa Y, Ikegami H, Sakata M, Mizutani T, Morishige K, Kurachi H, et al. Ovariectomy increases the level of estrogen receptor mRNA and estrogen receptor binding sites in female rat adipose tissue. J Endorinol Invest 1993;16:579-83.
36. Roudebush RE, Magee DE, Benslay DN, Bendele AM, Bryant HU. Effect of weight manipulation on bone loss due to ovariectomy and the protective effects of estrogen in the rat. Calcif Tissue Int 1993;53:61-4.
37. Morin LP, Fleming AS. Variation of food intake and body weight with estrous cycle, ovariectomy, and estradiol benzoate treatment in hamsters. J Comp Physiol Psychol 1978;92:1-6.
38. Mueller K, Hsiao S. Estrus- and ovariectomy-induced body weight changes: evidence for two estrogenic mechanisms. J Comp Physiol Psychol 1980;94:1126-36.
39. Laudenslager ML, Wilkinson CW, Carlisle HJ, Hammel HT. Energy balance in ovariectomized rats with and without estrogen replacement. Am J Physiol 1980;238:R400-5.
40. Clark RC, Tarttelin MF. Some effects of ovariectomy and estrogen replacement on body composition in the rat. Physiol Behav 1982;28:963-9.
41. Writing group for the Women's Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
42. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154-64.